Erratum: Interaction between Aβ peptide and α synuclein: Molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease (Neurochemical Research DOI: 10.1007/s11064-006-9140-9);Interaction between Aβ peptide and α synuclein: Molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease

Neurochemical Research

Volumn 31, Issue 9, 2006, Pages 1153-1162

  Mandal, Pravat K ^a   Pettegrew, Jay W ^a   Masliah, Eliezer ^b   Hamilton, Ronald L ^c   Mandal, Ratna ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; A peptide; Dementia with Lewy bodies; NMR; Parkinson's disease; Syn

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; PROTEIN PRECURSOR; PROTON; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ARTICLE; BINDING SITE; DEMENTIA; LEWY BODY; MOLECULAR DYNAMICS; MOLECULAR MIMICRY; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTON NUCLEAR MAGNETIC RESONANCE; AMINO ACID SEQUENCE; BRAIN; CYTOLOGY; DIFFUSE LEWY BODY DISEASE; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; NUCLEAR MAGNETIC RESONANCE; PATHOLOGY; PATHOPHYSIOLOGY;

ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOID BETA-PROTEIN; BRAIN; HUMANS; LEWY BODY DISEASE; MOLECULAR SEQUENCE DATA; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PARKINSON DISEASE; PEPTIDE FRAGMENTS;

EID: 33748584602     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11064-007-9391-0     Document Type: Erratum

References (48)

1. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388:839-840
2. Goedert M (2001) Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2:492-501
3. George JM (2002) The synucleins. Genome Biol 3:REVIEWS3002 (abstract)
4. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276:2045-2047
5. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O (1998) Ala30-Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18:106-108
6. Uversky VN, Li J, Souillac P, Millett IS, Doniach S, Jakes R, Goedert M, Fink AL (2002) Biophysical properties of the synucleins and their propensities to fibrillate - inhibition of alpha-synuclein assembly by beta- and gamma-synucleins. J Biol Chem 277:11970-11978
7. Eliezer D, Kutluay E, Bussell R, Browne G (2001) Conformational properties of alpha-synuclein in its free and lipid-associated states. J Mol Biol 307:1061-1073
8. Shults CW (2006) Lewy bodies. Proc Natl Acad Sci USA 103:1661-1668
9. Chandra S, Chen XC, Rizo J, Jahn R, Sudhof TC (2003) A broken alpha-helix in folded alpha-synuclein. J Biol Chem 278:15313-15318
10. Lee HJ, Choi C, Lee SJ (2002) Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J Biol Chem 277:671-678
11. Iversen LL, Mortishiresmith RJ, Pollack SJ, Shearman MS (1995) The toxicity in-vitro of beta-amyloid protein. Biochem J 311:1-16
12. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 82:4245-4249
13. Selkoe DJ (1994) Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease. Annu Rev Cell Biol 10:373-403
14. Mandal PK, Pettegrew JW (2004) Alzheimer's disease: soluble oligomeric Aβ(1.40) peptide in membrane mimic environment from solution NMR and circular dichroism studies. Neurochem Res 29:2255-2260
15. Coles M, Bicknell W, Watson AA, Fairlie DP, Craik DJ (1998) Solution structure of amyloid beta-peptide(1-40) in a water-micelle environment. Is the membrane-spanning domain where we think it is? Biochemistry 37:11064-11077
16. Shao HY, Jao SC, Ma K, Zagorski MG (1999) Solution structures of micelle-bound amyloid beta-(1-40) and beta-(1-42) peptides of Alzheimer's disease. J Mol Biol 285:755-773
17. Mandal PK, Pettegrew JW (2004) Alzheimer's disease: NMR studies of asialo (GM1) and trisialo (GT1b) ganglioside interactions with A beta(1-40) peptide in a membrane mimic environment. Neurochem Res 29:447-453
18. Pettegrew JW, Mandal PK, Panchalingam K, McClure RJ (2005) Catalytic breakdown of glycerophosphocholine by a peptide. Society for Neuroscience, Washington
19. Mandal PK, Pettegrew JW (2006) Evidence of catalytic type activity of Abeta peptide (manuscript under preparation)
20. Selkoe DJ (1999) Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399:A23-A31
21. Jarrett JT, Berger EP, Lansbury PT Jr (1993) The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32:4693-4697
22. Dickson DW (1997) The pathogenesis of senile plaques. J Neuropathol Exp Neurol 56:321-339
23. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47:1113-1124
24. McKeith IG, Burn DJ, Ballard CG, Collerton D, Jaros E, Morris CM, McLaren A, Perry EK, Perry R, Piggott MA, O'Brien JT (2003) Dementia with Lewy bodies. Semin Clin Neuropsychiatry 8:46-57
25. Yokota O, Terada S, Ishizu H, Ujike H, Ishihara T, Nakashima H, Yasuda M, Kitamura Y, Ueda K, Checler F, Kuroda S (2002) NACP/alpha-synuclein, NAC, and beta-amyloid pathology of familial Alzheimer's disease with the E184D presenilin-1 mutation: a clinicopathological study of two autopsy cases. Acta Neuropathol 104:637-648
26. Liu CW, Giasson BI, Lewis KA, Lee VM, DeMartino GN, Thomas PJ (2005) A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation - implications for pathogenesis of Parkinson disease. J Biol Chem 280:22670-22678
27. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L (2000) Dopaminergic loss and inclusion body formation in alphasynuclein mice: implications for neurodegenerative disorders. Science 287:1265-1269
28. Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, Mucke L (2001) Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci USA 98:12245-12250
29. Marion D, Wuthrich K (1983) Application of phase sensitive two-dimensional correlated spectroscopy (COSY) for measurements of 1H-1H spin-spin coupling constants in proteins. Biochem Biophys Res Commun 113:967-974
30. Piotto M, Saudek V, Sklenar V (1992) Gradient-tailored excitation for single-quantum NMR-spectroscopy of aqueous-solutions. J Biomol NMR 2:661-665
31. Mandal PK, Majumdar A (2004) A comprehensive discussion of HSQC and HMQC pulse sequences. Concepts Magn Reson A 20A:1-23
32. Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, Bax A (1995) NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J Biomol NMR 6:277-293
33. Garrett DS, Powers R, Gronenborn AM, Clore GM (1991) A common sense approach to peak picking two-, three- and four-dimensional spectra using automatic computer analysis of contour diagrams. J Magn Reson 95:214-220
34. Goddard TD, Kneller DG (1994) SPARKY 3. University of California, San Francisco
35. Hansen L, Salmon D, Galasko D, Masliah E, Katzman R, DeTeresa R, Thal L, Pay MM, Hofstetter R, Klauber M et al (1990) The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology 40:1-8
36. Galasko D, Hansen LA, Katzman R, Wiederholt W, Masliah E, Terry R, Hill LR, Lessin P, Thal LJ (1994) Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch Neurol 51:888-895
37. Arima K, Ueda K, Sunohara N, Hirai S, Izumiyama Y, Tonozuka-Uehara H, Kawai M (1998) Immunoelectron-microscopic demonstration of NACP/alpha- synucleinepitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies. Brain Res 808:93-100
38. Kosaka K, Yoshimura M, Ikeda K, Budka H (1984) Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree - a new disease? Clin Neuropathol 3:185-192
39. Gibb WR, Esiri MM, Lees AJ (1987) Clinical and pathological features of diffuse cortical Lewy body disease (Lewy body dementia). Brain 110(Pt 5):1131-1153
40. Gibb WR, Luthert PJ, Janota I, Lantos PL (1989) Cortical Lewy body dementia: clinical features and classification. J Neurol Neurosurg Psychiatry 52:185-192
41. Perry RH, Irving D, Blessed G, Fairbairn A, Perry EK (1990) Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J Neurol Sci 95:119-139
42. Hashimoto M, Rockenstein E, Crews L, Masliah E (2003) Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases. Neuromolecular Med 4:21-35
43. Jensen PH, Nielsen MS, Jakes R, Dotti G, Goedert M (1998) Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J Biol Chem 273:26292-26294
44. Iwai A, Yoshimoto M, Masliah E, Saitoh T (1995) Non-A beta component of Alzheimer's disease amyloid (NAC) is amyloidogenic. Biochemistry 34:10139-10145
45. Sidhu A, Wersinger C, Vernier P (2004) Alpha-synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease. FEBS Lett 565:1-5
46. Bennett MC, Bishop JF, Leng Y, Chock PB, Chase TN, Mouradian MM (1999) Degradation of alpha-synuclein by proteasome. J Biol Chem 274:33855-33858
47. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, Muller-Hill B (1987) The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325:733-736
48. Narayanan V, Scarlata S (2001) Membrane binding and self-association of alpha-synucleins. Biochemistry 40:9927-9934